Rociletinib shows promising activity against treatment-resistant EGFR-mutated lung cancer

A new targeted therapy drug against EGFR-mutation driven lung tumors that have become resistant to current therapies shows activity against the most common resistance mutation, significantly improving outcomes for patients.